Van ECK Associates Corp Acquires 114,769 Shares of Moderna, Inc. (NASDAQ:MRNA)

Van ECK Associates Corp raised its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 75.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 266,929 shares of the company’s stock after acquiring an additional 114,769 shares during the quarter. Van ECK Associates Corp’s holdings in Moderna were worth $17,839,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. boosted its position in shares of Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after acquiring an additional 5,129,800 shares during the period. International Assets Investment Management LLC boosted its holdings in Moderna by 10,687.1% in the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after purchasing an additional 316,552 shares during the period. Intech Investment Management LLC grew its position in shares of Moderna by 1,212.9% during the 1st quarter. Intech Investment Management LLC now owns 330,805 shares of the company’s stock valued at $35,251,000 after purchasing an additional 305,609 shares in the last quarter. Matrix Capital Management Company LP increased its holdings in shares of Moderna by 60.8% in the first quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock worth $77,789,000 after purchasing an additional 276,000 shares during the period. Finally, Motley Fool Wealth Management LLC purchased a new stake in shares of Moderna in the first quarter worth $21,317,000. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares in the company, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 715 shares of Moderna stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the sale, the chief financial officer now owns 9,505 shares in the company, valued at approximately $571,440.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,184 shares of company stock valued at $238,531. 15.20% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have weighed in on MRNA shares. UBS Group lowered their price target on Moderna from $140.00 to $108.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. The Goldman Sachs Group dropped their target price on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Jefferies Financial Group lowered their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research note on Tuesday, October 15th. Piper Sandler cut their target price on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a research report on Thursday, September 19th. Two research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $94.00.

Moderna Trading Down 0.5 %

Shares of Moderna stock opened at $53.29 on Wednesday. The company has a fifty day moving average of $63.53 and a 200 day moving average of $100.31. Moderna, Inc. has a fifty-two week low of $52.08 and a fifty-two week high of $170.47. The company has a market capitalization of $20.48 billion, a P/E ratio of -3.46 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.